dailyai.report

Engineered proteins for biologic medicines typically require years of expensive, high-failure research. New AI tools now predict protein structures and interactions to bypass traditional trial-and-error. MIT Tech Review highlights how these systems identify viable candidates faster. This shift reduces R&D costs and increases the probability that novel therapies reach patients in clinical trials.